HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Policy Power Challenged In House Examination Of Untitled Letters

This article was originally published in The Rose Sheet

Executive Summary

Oversight and Investigations Subcommittee Chairman Murphy wants to know if FDA is aware of consequences of publishing letters during stock trading hours. The Energy and Commerce Committee is examining whether the agency's use of untitled letters is “fair, effective and efficient in gaining compliance,” he says.

You may also be interested in...



Internet Searching May Get ‘Riskier’ For Patients After FDA Citations

“Sponsored searches” need to contain risk information, agency tells 14 firms in letters covering 48 products.

ANDA Approval Records Likely To End

CDER director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.

ANDA Approval Records Will End As US FDA Mops Up Backlog

CDER Director Woodcock says generic approvals remain inflated by applications that languished before FDA’s user fee program began, but as sponsors work through their own backlog of FDA responses, the number of ANDAs cleared by the agency appears likely to fall.

UsernamePublicRestriction

Register

RS019528

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel